Hikal Limited (NSE: HIKAL) announced today that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a Certificate of GMP Compliance to its active pharmaceutical ingredient (API) facility in Bengaluru. This certification confirms the facility’s adherence to Good Manufacturing Practice (GMP) requirements under the Mutual Recognition Agreement between the European Union and Switzerland. The certification follows successful inspections by Brazil’s ANVISA and Japan’s PMDA, reinforcing the site’s standing with leading global regulators.

Enhanced Global Regulatory Standing

The Swissmedic certification strengthens Hikal’s global regulatory standing and expands access to European and other regulated markets. This development is a significant step in the company’s strategy to diversify its geographic footprint in the pharmaceutical business, building resilience against geopolitical and trade uncertainties.

Strategic Importance

Commenting on the development, Mr. Sameer Hiremath, Chairman & Managing Director of Hikal Limited, stated: ‘The Swissmedic certification is a strong endorsement of the quality systems at our Bengaluru facility. It is an important step in expanding the global reach of our pharmaceutical business and opens new opportunities with customers in Europe and other regulated markets. Quality, compliance, and manufacturing excellence remain the foundation of our long-term customer partnerships.’ This recognition is part of Hikal’s broader strategy to enhance its global presence and cater to a wider customer base across regulated markets.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Hikal Limited

Hikal Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Hikal holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 4 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 60% of its 52-week range with RSI at 48. In other words, neither side has a clear edge right now. The stock holds up despite -5.4% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Hikal Limited.

Sun Pharmaceutical Industries Limited (SUNPHARMA) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA® (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA). This approval marks a significant milestone for Sun Pharma, expanding the use of ILUMYA beyond moderate-to-severe plaque psoriasis.

Expanding Therapeutic Reach

ILUMYA, an IL-23 inhibitor, is now an option for adults with active psoriatic arthritis who require healthcare provider-administered treatment. This approval is supported by Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies, which demonstrated the efficacy and safety of ILUMYA after two doses at 24 weeks in adult patients with active psoriatic arthritis.

Clinical Insights and Safety

The safety data in the studies were consistent with the well-documented safety profile of ILUMYA. No new safety signals were identified. However, ILUMYA may increase the risk of infection, and patients should be evaluated for tuberculosis (TB) infection prior to initiating treatment. The most common adverse reactions include upper respiratory infections, injection site reactions, and diarrhea for plaque psoriasis, and upper respiratory tract infections and COVID-19 for psoriatic arthritis.

This approval underscores Sun Pharma’s commitment to addressing complex chronic diseases and providing innovative therapeutic options for patients. With this milestone, Sun Pharma continues to strengthen its portfolio in psoriatic disease, offering hope and improved management for millions affected by these conditions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Sun falls 9.0% over three months and has not found a floor yet. The PEG reaches 3.29. The stock trades on brand and index weight, not on growth. Premium net margins of 20.2% demonstrate strong cost discipline and a wide competitive moat. The stock holds at 38% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. Revenue grows at 10.4% and profits at 10.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 9.0% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sun Pharmaceutical Industries Limited.

Indegene Limited (INDGN), the strategic operating partner to the global life sciences industry, announced its financial results for the quarter ended September 30, 2026. Indegene’s Q2 FY27 performance showcased a robust revenue growth of 39.5% year-on-year (YoY) in INR, translating to a 27.5% YoY increase in USD. This marks the fifth successive quarter of above 5% sequential growth. The company’s revenue for the quarter stood at ₹11,223 million ($117.5 million), with an EBITDA of ₹1,873 million, marking a 32.0% YoY increase. Moreover, H1 USD revenue growth reached a four-year high, reflecting the company’s sustained deal momentum and favorable industry tailwinds.

Revenue and Profitability

Indegene’s revenue from operations increased significantly to ₹11,223 million, up from ₹8,042 million in the same quarter last year. The company’s EBITDA margin remained stable at 16.7%, despite wage hikes, while the profit after tax (PAT) grew by 10% YoY to ₹1,123 million. This strong performance is attributed to the expansion across top accounts and an increase in the number of $1 million+ clients to 59, including 13 in the $10M+ range.

Growth and Future Outlook

Manish Gupta, Chairman and CEO of Indegene, highlighted the company’s broad-based growth driven by expansion across top accounts and significant deal wins in GenAI-enabled transformation and upstream engagements. Suhas Prabhu, CFO, noted that with a healthy pipeline and sustained deal momentum, Indegene expects growth and margin expansion to come together in the second half. The company anticipates EBITDA to grow faster than revenue in the coming quarters, supported by higher yields on investments and lower amortization.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Indegene Limited

Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.

Indegene gains 17.1% over three months and trades near its 52-week highs. The PEG of 2.45 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock trades at 86% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 17.1% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.